Tindamax

(Tinidazole)

Phase 3Small molecule

MMission Pharmacal

Tindamax is one of 73 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Bacterial VaginosisActive, not recruiting

HysterectomyActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Bacterial VaginosisPhase 3

Active, not recruiting

HysterectomyPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Tindamax

MMission Pharmacal

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Tafasitamab

Incyte

Preclinical

7 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

AIN

NCT07088419

Clinical

Trials by Indication[1]

Helicobacter Pylori4 trials

Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT04264663·250 enrolled

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Unknown status·YYanqing Li·Phase 4·NCT03139253·120 enrolled

Effectiveness of Rifabutin for Treatment of Helicobacter Pylori

Unknown status·RRabin Medical Center·Phase 3·NCT04652284·300 enrolled

Show 1 more trial

The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

Completed·KKirby Institute·Phase 4·NCT04132479·313 enrolled

Bacterial Vaginosis3 trials

Treatment of Bacterial Vaginosis With Oral Tinidazole

Completed·MMission Pharmacal·Phase 3·NCT00229216·200 enrolled

Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

Completed·UUniversity of Pittsburgh·Phase 1·NCT00510614·37 enrolled

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

Withdrawn·KKaiser Permanente·Phase 2·NCT00324142

Infections1 trial

Treatment of Giardia Lamblia Infections in Children

Terminated·HHelsinki University Central Hospital·Phase 4·NCT02942485·8 enrolled

Hysterectomy1 trial

Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy

Unknown status·UUniversity of Campinas, Brazil·N/A·NCT00787553·75 enrolled

Efficacy1 trial

Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax

Completed·WWalter Reed Army Institute of Research (WRAIR)·Phase 2·NCT00811096·20 enrolled

6 more indications

Fed1 trial

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

Completed·RRoxane Laboratories·Phase 1·NCT01591889·28 enrolled

First-line Treatment1 trial

Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT04122287·250 enrolled

Azithromycin1 trial

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00322465·305 enrolled

Lymphoma1 trial

Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003617·200 enrolled

AIN1 trial

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"

Recruiting·UUniversity of Washington·Phase 2·NCT07088419·40 enrolled

Antibiotics1 trial

Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men

Unknown status·UUniversity of Toronto·N/A·NCT03412071·125 enrolled

Regulatory

FDA Approval Timeline[4]

May 17, 2004

TINDAMAX

NDA NDA021618

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Tinidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinidazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinidazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021618). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Mission Pharmacal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMission Pharmacal

Tindamax

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Helicobacter Pylori4 trials

Bacterial Vaginosis3 trials

Infections1 trial

Hysterectomy1 trial

Efficacy1 trial

Fed1 trial

First-line Treatment1 trial

Azithromycin1 trial

Lymphoma1 trial

AIN1 trial

Antibiotics1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News